Oral Presentation 49th Lorne Conference on Protein Structure and Function 2024

Using nanobodies to improve drug delivery across the blood-brain barrier (#24)

Gabby Watson 1 2 , Duong Nhu 1 2 , Niva Jayakrishnan 1 , Pranav Runwal 3 , Michael Mlodzianoski 1 2 , Joseph Nicolazzo 3 , Kelly Rogers 1 2 , Guillaume Lessene 1 2 , Wai-Hong Tham 1 2
  1. WEHI, Parkville, VIC 3052, Australia
  2. Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia
  3. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
Publish consent withheld
  1. Yalamarty, S. S. K.; Filipczak, N.; Li, X.; Subhan, M. A.; Parveen, F.; Ataide, J. A.; Rajmalani, B. A.; Torchilin, V. P., Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). Cancers (Basel) 2023, 15.
  2. Moujalled, D., Southon, A. G., Saleh, E., Brinkmann, K., Ke, F., Iliopoulos, M., Cross, R. S., Jenkins, M. R., Nhu, D., Wang, Z., Shi, M. X., Kluck, R. M., Lessene, G., Grabow, S., Bush, A. I., and Strasser, A. (2022) BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells. Cell Death Differ 29, 1335-1348
  3. Pardridge, W. M. (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2, 3-14